Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.04% | 56.92% | 103.24% | 40.45% | 27.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.67% | 14.78% | 53.47% | 83.34% | 133.78% |
| Operating Income | -12.67% | -14.78% | -53.47% | -83.34% | -133.78% |
| Income Before Tax | -12.71% | -12.18% | -49.45% | -77.93% | -126.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.71% | -12.18% | -49.45% | -77.93% | -126.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.71% | -12.18% | -49.45% | -77.93% | -126.79% |
| EBIT | -12.67% | -14.78% | -53.47% | -83.34% | -133.78% |
| EBITDA | -120.39% | -135.04% | -345.75% | -114.75% | -19.70% |
| EPS Basic | 41.76% | 40.18% | 28.84% | -3.76% | -43.40% |
| Normalized Basic EPS | 41.76% | 40.18% | 28.84% | -3.76% | -43.40% |
| EPS Diluted | 41.76% | 40.18% | 28.84% | -3.76% | -43.40% |
| Normalized Diluted EPS | 41.76% | 40.18% | 28.84% | -3.76% | -43.40% |
| Average Basic Shares Outstanding | 131.24% | 82.83% | 114.89% | 99.60% | 81.46% |
| Average Diluted Shares Outstanding | 131.24% | 82.83% | 114.89% | 99.60% | 81.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |